E-mail us:
service@prospectnews.com
Or call: 212 374 2800
Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
Add to balance / Manage account
Not logged in
Prospect News home
>
Main news index
>
All issuers starting with C
>
Issuers starting with C, DD only
>
All stories on Clarus Therapeutics, Inc.
>
Stories on Clarus Therapeutics, Inc., DD only
Search again
Enter part or all of the issuer name:
Market:
All markets
No structured products
Bank loans
Canadian bonds
CLOs
Convertibles
Distressed debt
Emerging markets
High yield
Investment grade
Liability management
Municipals
PIPEs
Preferreds
Private placements
All leveraged markets
Structured products
Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each.
All others are $1.00 each. Headlines in
gray
are not currently covered by your subscription.
Clarus Therapeutics, Inc.
2/22/2023
DD
Clarus Therapeutics reports $24,573 net loss for January
1/24/2023
DD
Clarus Therapeutics reports $1.41 million net loss for December
12/22/2022
DD
Clarus Therapeutics reports $832,376 net loss for November
9/22/2022
DD
Clarus Therapeutics gets OK of bid procedures for testosterone drug
9/16/2022
DD
Clarus Therapeutics official committee of unsecured creditors formed
9/9/2022
BKCVDDEMHY
Prospect News reports three new defaults for Sept. 1-Sept. 7
9/6/2022
DD
Clarus Therapeutics files Chapter 11 bankruptcy, will auction testosterone drug
©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.
